KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer
Eklund, E. A.; Mourad, A.; Wiel, C.; Fagman, H.; Hallqvist, A.; Sayin, V. I.
Show abstract
BackgroundKRAS mutation status, stage and tumor size at the time of diagnosis are well-established independent prognostic factors in non-small cell lung cancer (NSCLC). Here, we investigate the prognostic value of combining survival data on KRAS mutation status and tumor size in early-stage NSCLC. MethodsWe studied the combined impact of KRAS mutational status and tumor size on overall survival (OS) and risk of death in patients with stage I-II NSCLC. We performed a retrospective study including 310 consecutively diagnosed patients with early (stage I-II) NSCLCs. All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the Vastra Gotaland region of western Sweden were included in this multi-center retrospective study. The primary study outcome was OS and risk of death (hazard ratio). ResultsOut of 310 patients with stage I-II NSCLC, 37% harbored an activating mutation in the KRAS gene. Our study confirmed staging and tumor size as prognostic factors. However, KRAS mutational status was not found to impact OS and there was no difference in the risk of death when combining KRAS mutational status and primary tumor size. ConclusionsIn our patient cohort, KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in stage I-II NSCLC.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.